|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2010-11-8
|
|
pubmed:abstractText |
5-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones have been identified with different combinations of 5-HT(1) autoreceptor antagonist and hSerT potencies and excellent rat PK profiles. The availability of tool compounds with a range of profiles at targets known to play a key role in the control of synaptic 5-HT levels will allow exploration of different pharmacological profiles in a range of animal behavioral and disease models.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:ArbanRobertoR,
pubmed-author:BertaniBarbaraB,
pubmed-author:BorrielloManuelaM,
pubmed-author:BromidgeSteven MSM,
pubmed-author:CapelliAnna-MariaAM,
pubmed-author:Di-FabioRomanoR,
pubmed-author:FaedoStefaniaS,
pubmed-author:GianottiMassimoM,
pubmed-author:GordonLaurie JLJ,
pubmed-author:GranciEnricaE,
pubmed-author:PasquarelloAlessandraA,
pubmed-author:SpadaSimone KSK,
pubmed-author:WorbyAngelaA,
pubmed-author:ZonziniLauraL,
pubmed-author:ZucchelliValeriaV
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7092-6
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
5-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3.
|
|
pubmed:affiliation |
Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, UK. steven.bromidge@evotec.com
|
|
pubmed:publicationType |
Journal Article
|
